Please login to the form below

Not currently logged in
Email:
Password:

Kanuma

This page shows the latest Kanuma news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at Alexion’s patents for Soliris

Amgen takes aim at Alexion’s patents for Soliris

Alexion’s other products such as lysosomal acid lipase deficiency treatment Kanuma (sebelipase alfa) and Strensiq (asfotase alfa) for hypophosphatasia have a long way to go before they bring in enough

Latest news

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    This agreement brings access to Kanuma (sebelipase alfa) which is in registration for the treatment of lysosomal acid lipase (LAL) deficiency. ... Corporate acquisition. Rare diseases portfolio including Kanuma (sebelipase alpha) for LAL deficiency.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics